logo
UAE: After losing first baby to rare genetic disorder, Dubai couple welcomes miracle child via IVF

UAE: After losing first baby to rare genetic disorder, Dubai couple welcomes miracle child via IVF

Khaleej Times27-02-2025
When Aysha and Ahmed (names changed upon request) married in 2019, they were excited about their future and planned to grow their family. Aysha soon conceived, and the couple was overjoyed.
However, their happiness was short-lived as one of the several tests during pregnancy revealed that the foetus was affected by Beckwith-Wiedemann Syndrome (BWS). The couple's first child did not survive.
Beckwith-Wiedemann Syndrome is a genetic condition that causes excessive growth in different body parts. Babies born with BWS are often larger than usual, and some may experience disproportionate growth on one side of the body, a condition known as hemihyperplasia.
Although children affected by BWS may grow taller than their peers, the condition typically slows down by age 8, and adult height tends to be normal. Despite the promising recovery with age, BWS increases the risk of childhood cancers, making it a difficult condition for parents.
Aysha and Ahmed, originally from Jordan and long-time residents of Dubai, were heartbroken after losing their first child. But they were determined not to let the condition affect their future children.
'We learned that one of us carried the genetic mutation for BWS. We really wanted a healthy pregnancy and child, so we decided to go for in vitro fertilisation (IVF),' said Aysha.
After undergoing IVF treatment, Aysha and Ahmed were able to welcome a healthy baby boy. Their son was free from the genetic disorder thanks to advanced fertility treatments and genetic testing. "We are very happy that our son is healthy and disease-free," said the mother.
The couple consulted doctors at Orchid Fertility Clinic, where the team used Preimplantation Genetic Testing for Monogenic Diseases (PGT-M) to prevent the hereditary condition from being passed down.
Dr Dimitrios Kafetzis, the medical director at Orchid Fertility, explained the challenges the couple faced, including advanced maternal age and a history of miscarriages. 'Our team employed a combination of advanced genetic screening and IVF techniques to help the couple conceive a healthy child while minimising the risk of passing on BWS,' said Dr Kafetzis.
The IVF process began with ovarian stimulation over four cycles, resulting in the retrieval of 57 mature eggs. These eggs were fertilised via Intracytoplasmic Sperm Injection (ICSI), and 41 embryos developed. 'Genetic testing identified seven embryos that were free of the BWS mutation, and further screening for chromosomal abnormalities narrowed the selection down to two viable embryos, one of which was successfully implanted,' said Dr Kafetzis.
'The pregnancy progressed well, and the baby was born healthy,' said Maria Banti, lab director at Orchid Fertility. 'This case demonstrates the potential of reproductive genetics in preventing inherited conditions and ensuring better outcomes for families facing genetic challenges.'
Now, the couple is determined to expand their family. They have embarked on their second round of IVF, hopeful that they will be blessed with another child free from genetic disorders.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Egypt, Novartis explore expanding collaboration in oncology, cardiology
Egypt, Novartis explore expanding collaboration in oncology, cardiology

Zawya

time6 days ago

  • Zawya

Egypt, Novartis explore expanding collaboration in oncology, cardiology

Egypt - Ahmed El-Sobky, Chairperson of Egypt's General Authority for Healthcare and supervisor of the Universal Health Insurance Project, met on Sunday with Gehan El-Emary, Chairperson and Managing Director of Novartis Egypt, to follow up on the progress of a memorandum of understanding (MoU) signed in February. The MoU, which aims to enhance cancer care, broaden cardiology collaboration, and promote medical training, has seen significant developments, according to an official statement from the Authority. El-Sobky highlighted the authority's goal to transform the Aswan Oncology Center into a leading regional and research hub for cancer treatment, with the involvement of international partners, including Novartis. During the meeting, El-Sobky extended a formal invitation to Novartis officials to visit the center and explore potential areas for further collaboration on-site. The meeting also focused on efforts to modernize clinical protocols for heart disease and breast cancer, alongside expanding training programs for healthcare providers in line with global best practices. El-Sobky emphasized the importance of increasing the number of physicians benefiting from these programs in partnership with Novartis to strengthen healthcare delivery across Egypt. In addition, the two sides discussed the possibility of launching a certified digital training platform designed to equip family doctors with the tools and skills necessary to manage non-communicable diseases such as hypertension, diabetes, and chronic heart conditions. They also explored innovative strategies to raise public health awareness and ensure continuity of care in underserved areas. Gehan El-Emary expressed pride in the growing partnership between Novartis and the General Authority for Healthcare, noting the tangible successes achieved through their joint initiatives. She reaffirmed Novartis's ongoing commitment to expanding its collaboration with the Authority, particularly in the areas of early detection, cancer care, cardiology, and chronic disease management.

Shanghai Healthcare M&A Fund Strategically Acquires Chengdu Kanghua Biological, Establishing a Fully Integrated Ecosystem
Shanghai Healthcare M&A Fund Strategically Acquires Chengdu Kanghua Biological, Establishing a Fully Integrated Ecosystem

Zawya

time21-07-2025

  • Zawya

Shanghai Healthcare M&A Fund Strategically Acquires Chengdu Kanghua Biological, Establishing a Fully Integrated Ecosystem

HONG KONG SAR - Media OutReach Newswire - 21 July 2025 - Chengdu Kanghua Biological Products Co., Ltd. (Stock Code: announced that Shanghai Healthcare M&A Fund ("the M&A Fund") intends to acquire the Company through a strategic agreement. Leveraging its substantial resource and financial strength, the M&A Fund plans to support Kanghua Biological's established product portfolio, accelerate sales of its mature products, and develop industry synergies between Shanghai and Chengdu. The goal is to rapidly expand a diversified vaccine pipeline and build an integrated vaccine ecosystem that combines proven commercialized products with best-in-class R&D capabilities. Dual-Driven Strategy: "Commercialization + Innovation" to Build a Leading Vaccine Ecosystem The vaccine industry is an essential pillar of public health with high entry barriers, stringent oversight, and extended development cycles – all factors contributing to its significant growth potential. As a leading domestic vaccine producer, Kanghua Biological's flagship product - human diploid cell rabies vaccine – stands as China's first domestically developed premium vaccine with over a decade of safe application, established market presence and nationwide distribution. The Company also maintains a robust global innovation pipeline, having successfully licensed its recombinant hexavalent norovirus vaccine overseas. This strategic acquisition, focused on critical segments of the vaccine value chain, will strengthen its strategic positioning. The M&A Fund is committed to supporting Kanghua Biological in leveraging its core product line while harnessing the combined strengthens of Shanghai and Chengdu to accelerate the formation of a next-generation vaccine industry ecosystem. Twin-City Collaboration: Combining "R&D + Manufacturing" to Create a New Industrial Framework This acquisition marks a significant step to drive Shanghai and Chengdu biopharmaceutical cooperation. Post-transaction, Kanghua Biological will capitalize on Shanghai's advanced R&D resources and access to top-tier scientific talent and global capital to enhances its industrial capabilities, manufacturing capacity, and market penetration. The M&A Fund will consolidate diverse industrial assets to promote Kanghua Biological's integration with Shanghai's R&D and clinical networks, creating an end-to-end collaborative system that spans from "clinical R&D to commercialization" and accelerates the development of a full industrial value chain. Dual-Channel Empowerment: Driving Corporate Value through "M&A + Integration" "This transaction goes beyond a typical corporate acquisition, it represents a transformative catalyst for industrial upgrading," commented Li Chen, Co-President of the M&A Fund."This exemplifies the complementary strengths created by resource-empowered consolidation. With deep biopharmaceutical, financial, R&D, and global network expertise, Shanghai Healthcare M&A Fund will create significant synergies with Kanghua Biological's technologies, products, manufacturing, and domestic distribution to have an outsized impact on the sector." Hashtag: #SIICCapital #ChengduKanghuaBiological #ShanghaiHealthcareM&AFund The issuer is solely responsible for the content of this announcement. About Shanghai Healthcare M&A Fund A core component of Shanghai's state-owned capital fund network, Shanghai Healthcare M&A Fund is managed by SIIC Capital, a subsidiary of SIIC Group. The M&A Fund targets Shanghai's biopharmaceutical sector, aligning government policy objectives with industrial needs by fostering collaboration with leading industry companies, strengthening sector clusters, and enabling asset restructuring. Through capital infusion, improving governance, optimizing management, and executing M&A, the M&A Fund backs "anchor" companies to build complementary and reinforcing links in the value chain, driving the ongoing transformation of specialized subsectors. About Chengdu Kanghua Biological Products Co., Ltd. Chengdu Kanghua Biological Products Co., Ltd. is a biopharmaceutical company engaged in research, manufacture and commercialization of biological products. Established in 2004, the company operates an in-house testing center and GMP-certified bacterial and viral vaccine production facilities. Its marketed portfolio includes the ACYW135 meningococcal polysaccharide vaccine and a freeze-dried human diploid cell rabies vaccine. Kanghua holds GMP certification from China's National Medical Products Administration, has participated in numerous scientific research projects and has been granted patents for over 100 technologies. SIIC Capital

Abu Dhabi DoE launches summer safety warning
Abu Dhabi DoE launches summer safety warning

Arabian Business

time12-07-2025

  • Arabian Business

Abu Dhabi DoE launches summer safety warning

Abu Dhabi authorities have issued a summer safety warning over electrical and gas appliances as well as air conditioning equipment. The Abu Dhabi Department of Energy (DoE) has launched a new awareness campaign titled 'Your Safety is Our Priority' to promote safe and responsible energy consumption across the emirate. The campaign aims to educate both individuals and businesses on preventing electricity and gas-related risks, especially during peak usage months. Abu Dhabi summer safety Designed to reach a wide audience, the campaign will feature digital awareness content, educational workshops, and on-site visits in partnership with public and private sector entities. The initiative reflects the DoE's commitment to community safety and sustainable energy use, aligning with Abu Dhabi's broader energy strategy. Ahmed Alsayed Mohamed Sheebani, Executive Director of the Regulatory Affairs Petroleum Products Sector at the DoE, said: 'Safety in the use of energy sources is one of the fundamental pillars of our regulatory framework. Through this campaign, we aim to enhance community awareness of best practices, and encourage safer, more sustainable behaviour in energy use, aligned with Abu Dhabi's vision to build an efficient and secure energy sector that serves both people and the environment. 'Collaboration between regulatory entities and the community is key to reducing gas-related incidents and ensuring everyone's safety.' Summer poses increased risks as air conditioners, appliances, and gas systems operate at higher loads, raising the chance of malfunctions or accidents. Abdul Rahman Al-Alawi, Health, Safety, and Environment Director at the DoE, said: 'At the start of summer, the difficulties linked to energy usage grow, be it inside residences or within commercial and service facilities. 'Our part, at the Department of Energy, is to foster a safe and sustainable environment in the emirate through sustained outreach and education. 'The Your Safety is Our Priority campaign is a clear manifestation of our duty to enhance a culture of safety, and to affirm that the conscious and responsible utilisation of energy is a joint responsibility between regulatory authorities and society. 'Prevention is rooted in community awareness. Therefore, this campaign was conceived to connect with people through straightforward language and actionable content that aids in reducing accidents and encourages the sustainable consumption of energy.' The campaign uses simple language and practical guidance to help residents: Safely manage electrical appliances and gas systems Reduce the risk of energy-related accidents Adopt energy-efficient habits that benefit both safety and sustainability The DoE is urging all residents, companies, and institutions in Abu Dhabi to actively support the campaign and help build a collective culture of energy safety.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store